No­var­tis ra­di­oli­gand tri­umphs in a first-line PhI­II tri­al re­cruit­ing pa­tients with rare neu­roen­docrine tu­mors

No­var­tis’ ra­di­oli­gand ther­a­py Lu­tathera has hit the pri­ma­ry end­point in a Phase III tri­al in new­ly di­ag­nosed pa­tients with a rare form of neu­roen­docrine tu­mors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER